Antineutrophil Cytoplasmic Antibody-associated Vasculitis Management 2020: Where Are We Now?

Jayne, David

View / Open Files

Accepted version (Microsoft Word 2007, 22Kb)

Authors

Jayne, David

Publication Date

2021-04

Journal Title

J Rheumatol

ISSN

0315-162X

Publisher

The Journal of Rheumatology

Volume

Issue

Pages

479-481

Language

eng

Type

Article

This Version

Physical Medium

Print-Electronic

Metadata

Show full item record

Citation

Jayne, D. (2021). Antineutrophil Cytoplasmic Antibody-associated Vasculitis Management 2020: Where Are We Now?. J Rheumatol, 48 (4), 479-481. https://doi.org/10.3899/jrheum.201351

Abstract

The management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has come a long way from the first postmortem descriptions of the diseases in the 1930s and 1950s1 Pivotal phases have been the introduction of glucocorticoids (GC) and cyclophosphamide (CYC), the association with ANCA in the 1980s, and consensus classification and nomenclature systems from 1990 onwards2.

Keywords

Humans, Antibodies, Antineutrophil Cytoplasmic, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Identifiers

External DOI: https://doi.org/10.3899/jrheum.201351

This record's URL: https://www.repository.cam.ac.uk/handle/1810/330740

Rights

Licence URL: http://www.rioxx.net/licenses/all-rights-reserved